Eurofins CDMO Alphora Invests in New 50,000 sq ft Biologics Facility in Canada

• Eurofins CDMO Alphora is building a 50,000 sq ft biologics manufacturing facility in Mississauga, Ontario.

• The facility will manufacture monoclonal antibodies and protein therapies, supported by Canada’s Strategic Initiative Fund.

Eurofins CDMO Alphora has announced plans to build a new biologics manufacturing facility in Mississauga, Ontario. The 50,000 sq ft GMP facility will produce monoclonal antibodies (mAbs) and protein therapies for clinical and commercial use. This development is part of an effort to enhance Canada’s biomanufacturing capabilities and pandemic preparedness.

Scheduled for completion in April 2026, the facility will be housed within a new 112,000 sq ft building on Eurofins’ 14-acre campus at Sheridan Research Park. The project is supported by the Federal Government of Canada through the Strategic Initiative Fund (SIF), aimed at strengthening Canada’s biologics ecosystem and local employment.

The facility will operate at the 2000L bioreactor scale, incorporating single-use technology and running in both fed-batch and perfusion modes. It will also include a sterile fill line capable of producing up to 24.9 million units annually. This investment follows the January 2024 opening of Eurofins’ Development & Pilot Scale-up facility.

This investment in the new manufacturing facility comes after Eurofins CDMO Alphora successfully launched its Development & Pilot Scale-up facility, which has been operational since January 2024. The biologics initiative represents a key advancement in Eurofins’ strategy to offer comprehensive, integrated solutions. Building on two decades of experience in developing and manufacturing therapeutics, the company aims to support both Canadian and global markets with a full range of services for life-saving and life-enhancing treatments.

With expertise in Active Pharmaceutical Ingredients (API) and Highly Potent Active Pharmaceutical Ingredients (HPAPI), Eurofins CDMO Alphora is well-positioned to offer both small and large molecule services under one roof, supporting the development of complex modalities like Antibody Drug Conjugates (ADCs).